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Abstract 
Background: Cow’s milk allergy (CMA) is one of the most common food allergies in 
children. Epigenetic mechanisms have been suggested to play a role in CMA pathogenesis. 
We shown that DNA methylation of Th1/Th2 cytokine genes and FoxP3 affects CMA disease 
course. Preliminary evidence suggest that also the miRNome could be implicated in the 
pathogenesis of allergy. Main study outcome was to comparatively evaluate miRNome in 
children with CMA and in healthy controls. Methods: Peripheral blood mononuclear cells 
were obtained from children aged 4-18 months: 10 CMA patients, 9 CMA patients who 
outgrew CMA, and 11 healthy controls. Small RNA libraries were sequenced using a next-
generation sequencing-based approach. Functional assessment of IL-4 expression was also 
performed. Results: Among the miRNAs differently expressed, 2 were up-regulated and 14 
were down-regulated in children with active CMA compared to healthy controls. miR-193a-
5p resulted the most down-regulated miRNA in children with active CMA compared to 
healthy controls. The predicted targets of miR-193a-5p resulted up-regulated in CMA 
patients compared to healthy controls. Peripheral blood CD4
+
 T cells transfected with a 
miR193a-5 inhibitor showed a significant up-regulation of  IL-4 mRNA and its protein 
expression. Children who outgrew CMA showed miRNA-193a-5p level, and its related 
targets expression, similar to that observed in healthy controls. Conclusions: Our results 
suggest that miR-193a-5p is a post-transcriptional regulator of IL-4 expression and could 
have a role in IgE-mediated CMA. This miRNA could be a novel diagnostic and therapeutic 
target for this common form of food allergy in childhood.  
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Background 
Cow’s milk allergy (CMA) is one of the most common food allergy (FA) in early 
childhood, with a significant increase in prevalence, persistence, severity of clinical 
manifestations and a consequent negative impact on quality of life and medical care costs (1). 
The evidence that FA could derive from a complex gene-environment interaction that induces 
epigenetic changes at immune system level (2,3) suggests that epigenetic mechanisms could 
represent a potential target of intervention. This lead the importance of a better definition of 
the epigenetic mechanisms involved in  CMA (4). Several allergy-related genes, including 
those related to T-effector pathways, namely IFN-γ and IL-4, have been found to be 
susceptible to epigenetic regulation (4,5). An epigenome-wide association study in children 
with CMA revealed alterations of methylation status in Th1-Th2 response mediator genes 
(i.e., IL1RL1, IL5RA, IL4, CCL18 and STAT4) in whole blood DNA, and their association 
with the disease (6). We demonstrated that epigenetic mechanisms, involving DNA 
methylation of the promoter region of the Type 1 helper (Th1) and Th2 cytokine genes and 
Treg-specific demethylated region of FoxP3 play a role in tuning the CMA disease course, 
and that dietary strategies could influence these mechanisms differentially (2,3). In addition 
to DNA methylation, there are also other epigenetic networks including micro RNAs 
(miRNAs).  They are small endogenous RNAs that shape gene expression and are transcribed 
from intergenic or intronic genomic loci which inhibits target gene expression by mRNA 
degradation or translational repression (7). Preliminary results suggest that also the 
miRNAome could be involved in the pathogenesis of allergy. Profiling studies of miRNAs in 
human biopsy specimens and in mouse models of allergy including asthma, eosinophilic 
esophagitis and contact dermatitis show differential expression in ~10–20% of miRNAs (8-
12). Selected miRNAs have been implicated in several regulatory mechanisms of Th2 
response, including sphingosine-1-phosphate receptor gene (S1pr1) expression and 
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suppression of Th1 differentiation (13-15). Other miRNAs have been implicated in allergy 
prevention through the induction of FoxP3
+
 Treg differentiation (16). miRNome in CMA is 
still largely unexplored. Identification of specific miRNAs and their targets will both 
facilitate our understanding of the regulation of key CMA determinants as well as offer the 
opportunity to identify novel targets for innovative diagnostic and therapeutic strategies. To 
address this issue, we comparatively investigated miRNA profile in CMA children and 
healthy controls using a next-generation sequencing (NGS)-based approach.  
 
Methods 
Study subjects  
IgE-mediated CMA children (aged 4-18 months), consecutively referred to our tertiary 
Pediatric Allergy Center from December 2012 to April 2014, for a diagnostic oral food 
challenge because recent evidence of suspected CMA signs and symptoms, were invited to 
participate into the study.  
 
All patients underwent a double-blind placebo-controlled oral food challenge (DBPCFC), as 
described previously (17). All oral food challenges took place at the Center on two separate 
days with a 1-week interval. Parents of children taking antihistamine were advised to 
withhold these medications for at least 72 h before and during the challenge. Randomization 
and preparation of the challenges were performed by experienced FA dieticians not directly 
involved in the procedures. Full emergency equipment and medications (epinephrine, 
antihistamines, and steroids) were available. The results were assessed simultaneously by 
three experienced pediatric allergists. Clinical symptoms occurring within 2 h of 
administering the highest dose were defined as “IgE-mediated reactions.” Only subjects with 
positive oral challenge were enrolled in the study. 
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During the same study period, subjects with a sure diagnosis of IgE-mediated CMA (aged 4-
18 months), visiting the Center to assess the possible occurrence of immune tolerance by the 
result of DBPCFC were also evaluated. Only subjects with negative oral food challenge were 
enrolled in the study. During the challenge procedure, a venous blood sample (4 ml) was 
obtained from all these patients. 
We excluded patients with concomitant suspected or confirmed diagnosis, according to 
validated criteria, of the following conditions: allergic disorders or food allergies other than 
CMA, eosinophilic disorders of the gastrointestinal tract, chronic systemic diseases, 
congenital cardiac defects, active tuberculosis, autoimmune diseases, immunodeficiency, 
chronic inflammatory bowel diseases, celiac disease, cystic fibrosis, metabolic diseases, food 
intolerance, malignancy, chronic pulmonary diseases, and malformations of the 
gastrointestinal tract.  During the same study period, consecutive healthy children (aged 4-18 
months), not at risk for atopic disorders (namely, without any first degree family member 
affected by allergy), attending our Department for minimal surgical procedures (phimosis, 
inguinal hernia repair, or cyst excisions), were enrolled as healthy controls. A venous blood 
sample (4 ml) was collected during pre-surgery evaluation procedures also from these 
subjects. They were assessed for the presence of FA and other allergic diseases at enrollment 
and 6 months after blood sampling by pediatric allergists at our Center. The same exclusion 
criteria were applied to healthy controls. In addition, all study subjects were also followed at 
our center for at least 12 months after blood sampling with the aim to confirm the absence of 
all exclusion criteria.   
The parents or guardians of the children enrolled gave their written informed consent to the 
study. The study was approved by the Ethics Committee of the University of Naples 
Federico II (Protocol number: NCT02062476). 
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Total serum IgE and specific IgE against cow’s milk proteins  
Serum was obtained by centrifugation for 15 min. Serum was flash frozen and stored at 
−80°C until analysis. Serum total IgE and specific IgE against cow’s milk proteins (alpha-
lactalbumin, beta-lactoglobulin, bovine serum albumin, casein, lactoferrin) were analyzed by 
enzymatic immunoassay (Phadia 100 ThermoFisher Scientific CAP system, Rodano Milano, 
Italy). Results were expressed as kilounits per liter (kU/l). 
 
RNA isolation and small RNA sequencing 
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral whole blood 
samples using the Ficoll-Paque (GE Healthcare, Uppsala, Sweden) method. Total RNA was 
isolated from PBMC samples using the Trizol Reagent kit (Invitrogen, Carlsbad, CA, USA) 
and quantified with the Nanodrop 2000c spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). RNA quality and integrity were assessed with the Experion RNA Standard Sense 
kit (Biorad, Hercules, CA, USA). All RNA samples had an RNA Quality Index ≥8. Small 
RNA library preparation was performed using the TruSeq Small RNA Sample Prep kit, 
according to the manufacturer’s indications (Illumina, San Diego, CA, USA), as previously 
described (18,19).  Briefly, 1 µg of total RNA from each sample was ligated to specific 
adapters, reverse transcribed and amplified to obtain a population of double-stranded cDNAs. 
During PCR amplification, barcode-tagged primer pairs were used to univocally tag each 
sample. The resulting cDNAs were size-selected on a 6% PAGE gel. In detail, the gel band 
corresponding to fragments ranging from 140 to 160 bp was excised, ethanol-precipitated and 
eluted in ultra-pure water. The libraries were then evaluated for quality on the Agilent 2100 
BioAnalyzer (Agilent, Santa Clara, CA, USA). Eleven libraries were pooled in equimolar 
amounts. Sequencing reactions were carried out using the MiSeq instrument (Illumina). The 
study population was analyzed in two separate sequencing experiments. 
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Bio-informatics analysis 
Each deep sequencing library was processed independently. The first step in the analysis 
workflow, after adapter trimming (Cutadapt tool v1.7.1) and sequence quality assessment 
(FastQC tool v0.11.2), was the alignment of the obtained reads to multiple human sequencing 
databases with the STAR tool v 2.3.1.2 (20) to the reference ncRNAs (fRNAdb, 
http://www.ncrna.org/frnadb/download) and the hg19 build of the human genome (UCSC 
Genome Browser, http://genome.ucsc.edu/cgi-bin/). After trimming the adaptor, the reads 
shorter than 15 and greater than 32 nucleotides were discarded. The reads were aligned to the 
reference miRNA precursors (miRBase v.21, http://www.mirbase.org/) with the SHiRMP 
tool (21). To identify and count mature miRNAs, the reads that mapped to miRNA precursors 
were aligned to the reference mature miRNA (miRBase v.21, http://www.mirbase.org/). 
Differential miRNA expression was evaluated with the DESeq2 tool (adjusted P<0.05); 
assuming a typical DESeq2 data frame, the miRNA read counts were normalized using the 
DESeq2 normalization method ‘sizeFactors’ (22). The putative miR-193a-5p target genes 
were predicted by DIANA-MICROT software (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r= microT_CDS/index), and the experimentally 
validated miR-193a-5p target genes and the miRNA-Target interaction network were 
obtained from miRTarBase database (http://mirtarbase.mbc.nctu.edu.tw/) (23). 
 
Quantitative real time PCR analysis 
Quantitative Real Time PCR (qRT-PCR) analysis of the miR-193a-5p, and of the RPL35A, 
TP73, ZC3H7B and C/EBPα genes was performed with the TaqMan miRNA assay kit and 
the TaqMan gene expression assay kit, respectively (both from Applied Biosystems, Grand 
Island, NY, USA) according to the manufacturer's instructions. Samples were run in duplicate 
at 95°C for 15 seconds and 60°C for 1 minute using an ABI Prism® 7900 Sequence 
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Detection System (Applied Biosystems). Data analysis was performed with the comparative 
threshold cycle (CT) method. In order to identify the most appropriate reference miRNA to 
use for data normalization, we evaluated the RNU6, miR-130 and miR-301b miRNAs, which 
were the most stable miRNAs also in sequencing raw data. The relative quantity of each 
miRNA in samples was calculated using the equation ΔCT = [CT miRNA (target) - CT miR-
301 (endogenous control)]. We used the GAPDH gene to normalize the level of mRNA 
expression. Student’s and ANOVA t-tests were used to determine differences among means. 
The StatView 5 software was used to generate the bar plot. 
 
Functional assessment of IL-4 expression depending on miR-193a-5p inhibition 
Ten ml of fresh heparinized peripheral blood were collected from a healthy human donor to 
evaluate IL-4 expression in CD4+ T-cells (mRNA) and supernatant (protein). Donor signed 
an agreement acknowledging that their blood may be used for research. After, red blood cells 
were lysed with ammonium chloride solution, peripheral blood cells were washed, 
immediately stained using anti-CD4 antibody (BD Biosciences, San Jose, California, USA) 
and sorted for CD4
+
 T-cell population selection. The isolated CD4
+
 T-cells were resuspended 
in Opti-MEM™ medium (Invitrogen – Life Technologies, Carlsbad, California, USA) for 
transfection experiment. In particular, 300 x 103 cells were cultured in one well of a 24-well 
plate and transfected with 10 μM of miR193a-5 inhibitor (mirVana™ miRNA Inhibitors, 
Ambion, Austin, TX, USA) combined with Lipofectamine RNAiMax (Invitrogen - Life 
Technologies, Carlsbad, California, USA), following the manufacture's instructions. As 
negative control, we used 300 x 103 not transfected cells. After 16 hours of incubation at 
37°C in a humidified atmosphere of air containing 5% CO2, T cell activation experiments 
were performed. In particular, transfection medium was replaced with Iscove’s Modified
Dulbecco’s culture Medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 20% 
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heat inactivated fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 4mM GlutaMAX™ 
(Invitrogen - Life Technologies, Carlsbad, California, USA), 100 U/ml penicillin and 100 
μg/ml streptomycin and only miR193a-5 inhibitor-transfected cells were stimulated with 
Dynabeads® Human T-Activator CD3/CD28 (Invitrogen - Life Technologies, Carlsbad, 
California, USA) for 3 days. After the 3 days of incubation, cells and supernatants derived 
from both transfected/stimulated state and untransfected/unstimulated condition (negative 
control) were collected to measure IL-4 at mRNA and protein level using respectively qPCR 
(TaqMan gene expression assay kit, Applied Biosystems, Grand Island, NY, USA) and 
ELISA (IL-4 ELISA Kit, human, Life Technologies, Carlsbad, California, USA), according 
to the manufactures' instructions. The assay was repeated twice.  
 
Results 
The main demographic and clinical features of children enrolled in the study are reported in 
Table 1. Small RNA deep sequencing generated a total of 27,155,643 high-quality filtered 
reads, of which 19,957,521 were successfully mapped, and 4,672,481 of these were uniquely 
mapped reads. Almost 85% of all uniquely mapped reads fall within the miRNA category. 
The size distribution pattern of these mapped reads was similar in all samples and the average 
read length was 22.6 nt (Table 2). We performed a differential expression analysis to assess 
differences between active CMA subjects and healthy controls. The heatmap shows the 
expression of miRNAs in all samples after unsupervised hierarchical clustering analysis of 
normalized data. Samples from the same study group were largely clustered together (Fig. 
1A). Accordingly, the principal component analysis revealed a separation between the two 
groups (Fig. 1B). Then ,we used the DESeq2 tool (www.bioconductor.org) to estimate the 
differential expression of miRNAs between groups. Among the miRNAs most differentially 
expressed between active CMA children and healthy controls, 2 were up-regulated and 14 
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were down-regulated (Table 3), and miR-193a-5p resulted the most down-regulated in active 
CMA children compared to healthy controls. Quantitative PCR confirmed that miR-193a-5p 
expression was significantly lower (P<0.05) in active CMA patients than in healthy controls 
(Fig. 1C).  
 
With the aim to investigate the functional consequences of miRNA-193a-5p down-regulation 
in active CMA, we identify the following four targets predicted by DIANA-MICROT 
software: RPL35A, TP73, ZC3H7B and C/EBP (Fig. 2A). These genes encode, 
respectively:  a component of the 60S ribosomal subunit; a member of the p53 family of 
transcription factors; a protein that contains a RNA-binding domain; and a transcription 
factor with a basic leucine zipper (bZIP) domain that recognizes the CCAAT motif in the 
promoters of target genes. (www.genecards.org). 
 
Quantitative PCR showed that the expression of three out of these 4 targets (RPL35A, 
ZC3H7B,TP73) was significantly up-regulated in active CMA patients if compared to healthy 
controls (see Fig. 2C-E). The C/EBPα transcript showed only a trend towards up-regulation 
in active CMA patients versus healthy controls (see Fig. 2B).  
 
Finally, to investigate whether miR-193a-5p could be involved in the regulation of Th2 
response in CMA, we assessed the effects of the inhibition of this particular miRNA on IL-4 
production by CD4+ T cells from a healthy donor. Cells were transfected with 10 μM of 
miR193a-5p inhibitor, and a significant up-regulation of  IL-4 mRNA expression and protein 
production were observed (Fig. 3).  
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Children who outgrew CMA showed miRNA-193a-5p expression profile similar to that 
observed in healthy controls. Quantitative PCR showed that the expression of the 4 targets 
(RPL35A,ZC3H7B,TP73) of this miRNA resulted also similar (data not shown).  
 
Discussion 
Using a NGS-based approach, we investigated the “miRNA signature” associated 
with IgE-mediated CMA. This signature was characterized by a miR-193a-5p four-fold 
decrease in children with active disease. Our results are in line with previous findings in 
allergic dermatitis (24), and with evidence on the role of miRNA-193a-3p in regulating the 
expression of pro-inflammatory cytokines in human gut and PBMCs (25,26). The pivotal role 
of miR-193a-5p in IgE-mediated allergic response is also supported by functional data on IL-
4 RNA expression and protein synthesis. These data open the road to new therapeutic 
opportunities targeting the miR-193a-5p in the context of CMA.  Interestingly, children who 
acquired immune tolerance showed miR-193a-5p level similar to that observed in healthy 
controls, suggesting that the expression of this miRNA could be influenced by the disease 
state. If this result will be confirmed in future studies, miR-193a-5p could become an easily 
accessible biomarker for monitoring the CMA disease course. 
The strengths of our study are related to a well chacterized study population and to the 
adoption of high quality and accurate testing. The main limitations are related to the 
relatively small number of observations, the cross-sectional design, and the PBMC-based 
evaluation. Longitudinal studies in larger cohorts of CMA children, from symptom onset to 
immune tolerance acquisition, including simultaneous investigations on different tissue and 
plasma samples could be useful to further confirm our results. Finally, the miRNome network 
involves a large number of regulatory pathways potentially involved in CMA , and further 
studies are advocated to assess the effect of miRNAs  interaction on CMA disease course. 
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In conclusion, our results suggest that miR-193a-5p is a post-transcriptional regulator of IL-4 
gene expression and could have a role in restraining IgE-mediated CMA. This miRNA could 
be a novel, possibly therapeutic, target for this very common form of FA in childhood.  
 
Abbreviations 
CMA: cow’s milk allergy;  
DBPCFC: double blind placebo-controlled food challenge; 
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Th: T helper;  
Th1: Type 1 helper; 
Th2: Type 2 helper; 
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IL-5:interleukin-5;  
IL-10: interleukin-10;  
INF-γ: interferon-γ;  
PBMCs: peripheral blood mononuclear cells 
miRNome: full spectrum of miRNAs expressed in a specific genome; 
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miRNA: micro RNA;  
EoE: eosinophilic esophagitis. 
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Table 1. Main demographic and clinical features of the study population 
 
 
Active CMA 
patients 
Healthy 
controls 
Subjects who 
outgrew CMA*  
N. 10 11 9 
 
Male, N. (%) 
 
7 (70) 
 
5 (45.4)  
 
6 (66.7) 
Age, months (SD) 5.5 (0.7) 8.2 (4.3) 17 (0.9)  
Body weight, kg (SD) 7.385 (964.7) 8.644 (3.570) 12.185 (554.9) 
Spontaneous delivery, N (%) 5 (50) 5 (45.5) 2 (22.2) 
Breast fed, ≤ 8 weeks, N (%)  10 (100) 11 (100) 9 (100) 
Symptoms at  CMA onset:    
Gastrointestinal, N (%) 4 (40) - 4 (44.4) 
Cutaneous, N (%) 8 (80) - 8 (88.9) 
Respiratory, N (%) 1 (10) - 3 (33.3)  
Total serum IgE, kU/l (SD) 260.6 (230.9) 0.2 (0.1) 272.3 (244.3) 
alpha-lactalbumin, kUA/l (SD) 6 (11.2) - 0.7 (0.7) 
beta-lactoglobulin,  kUA/l (SD) 4.5 (7.1) - 2.5 (3.6) 
bovine serum albumin,  kUA/l (SD) 5.4 (8.7) - 1 (1.9) 
casein,  kUA/l (SD) 22.7 (39.2) - 0.5 (0.4) 
Lactoferrin,  kUA/l (SD) 2 (6.1) - 0 
 
*In all these patients acquisition of immune tolerance, after treatment with extensively 
hydrolyzed casein formula containing the probiotic L. rhamnosus GG (Nutramigen LGG, 
Mead Johnson Nutrition, Evansville, IN, USA), was demonstrated by the results of oral food 
challenge. 
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Table 2. Small RNAs deep sequencing results. The table summarizes the sequencing raw 
data obtained for each analyzed sample, including the total number of reads (and their 
average length) and the number of mapped and uniquely mapped reads. The low-quality 
discarded reads are reported for each sample.  
Sample 
ID 
Study 
group 
Reads 
length 
(average) 
Total 
reads (N) 
Mapped 
reads (N) 
Uniquely 
mapped 
reads (N, 
%) 
Trimmed 
reads 
(%) 
Reads too 
short/long (N) 
1 Control 22.7 809,299 754,324 200,221 
(24.74) 
1.90% 2,314/52,661 
2 Control 22.64 977,404 943,305 30,386 
(3.10) 
1.20% 8,561/25,538 
3 Control 22.41 913,509 869,306 161,905 
(17.72) 
1.40% 4,716/39,487 
4 Control 22.36 1,010,87
7 
956,963 117,079 
(11.58) 
1.40% 5,850/48,064 
5 Control 22.17 723,265 629,458 63,901 
(8.83) 
1.00% 2,769/91,038 
6 Control 22.8 615,729 553,280 37,997 
(6.17) 
1.20% 4,810/57,639 
7 Control 22.85 591,532 471,934 75,287 
(12.72) 
1.60% 3,409/116,18
9 
8 Control 22.48 937,594 782,855 191,169 
(20.38) 
1.70% 826/153,913 
9 Control 22.84 2,094,12
1 
1,498,35
4 
450,670 
(21.52) 
1.50% 2,120/593,64
7 
10 Control 22.6 1,471,31
2 
1,194,34
0 
263,734 
(17.92) 
1.70% 768/276,204 
11 Control 22.94 3,694,58
9 
3,049,71
6 
956,642 
(25.89) 
1.80% 1,987/642,88
6 
12 CMA 22.39 1,163,19
8 
1,046,51
5 
329,420 
(28.32) 
1.60% 1,630/115,05
3 
13 CMA 22.75 1,335,83
3 
1,049,82
4 
205,514 
(15.38) 
1.50% 6,320/279,68
9 
14 CMA 22.35 694,018 656,621 44,682 
(6.43) 
2.20% 1,1298/26,09
9 
15 CMA 23.55 3,004,75
4 
295,705 55,113 
(1.83) 
0.40% 197/2,708,85
2 
16 CMA 22.41 509,618 493,502 81,052 
(15.90) 
1.40% 2,902/13,214 
17 CMA 22.55 844,123 756,700 86,758 
(10.27) 
1.70% 8,472/78,951 
18 CMA 22.59 1,309,81 1,167,87 286,678 2.00% 3,013/138,92
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4 2 (21.88) 9 
19 CMA 22.72 1,701,66
7 
1,568,06
7 
477,284 
(28.04) 
2.00% 2,979/130,62
1 
20 CMA 22.87 1,305,61
4 
1,192,97
8 
193,008 
(14.78) 
1.70% 11,528/101,1
08 
21 CMA 22.51 1,447,77
3 
1,272,98
7 
363,981 
(25.14) 
1.70% 982/173,804 
ID, identifiers; N, number. 
 
Table 3. Most significant down-regulated and up-regulated miRNAs in children with active 
cow’s milk allergy versus healthy controls.  
 
Mature* Chr Strand Log2(FC) pvalue (adj) 
miR-193a-5p chr17 1 -1.84 0.000276 
miR-197-3p chr1 1 -1.49 0.000062 
miR-423-5p chr17 1 -1.26 0.000276 
let-7b-5p chr22 1 -1.14 0.004 
miR-486-5p chr8 1 -1.08 0.0425 
miR-92b-3p chr1 1 -1.07 0.022 
let-7b-3p chr22 1 -1.05 0.0425 
miR-574-3p chr4 1 -1.04 0.0163 
miR-125a-5p chr19 1 -0.99 0.00381 
miR-93-3p chr7 -1 -0.94 0.0385 
miR-3615 chr17 1 -0.84 0.0385 
miR-423-3p chr17 1 -0.73 0.00172 
miR-320a chr8 -1 -0.70 0.0289 
miR-191-5p chr3 -1 -0.64 0.00625 
miR-30a-5p chr6 -1 1.08 0.00625 
miR-224-5p chrX -1 1.13 0.0144 
 
*Mature: ‘5p’ and ‘3p’ indicate the DNA arm of the miRNA precursor (from the 5' or from 
the 3', respectively) according to miRNA nomenclature 
(http://www.mirbase.org/help/nomenclature.shtml); Chr: chromosome; Log2 (FC): Log2 
(FoldChange); p value (adj): p value adjusted by Benjamini, Hochberg method. The DESeq2 
tool was used to estimate the differential expression of miRNAs between the two groups 
based on normalized read counts (p value adjusted<=0.1). 
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FIGURE LEGENDS 
Figure 1. miRNome differential analysis between active CMA patients and healthy 
controls.  
(A) Heat map representation showing hierarchical clustering of active CMA patients and 
controls on the basis of the high differentially expressed miRNAs. On the heat map vertical 
axis are reported the names of the most significant miRNAs differentially expressed between 
the two groups (adjusted p value <0.1) on the heat map horizontal axis, are the sample 
identification numbers. (B) Principal component analysis plot, based on miRNA expression 
of active CMA patients and healthy children, showing that almost all samples belong to the 
same condition are clustered together. (C) The relative expression of miR-193a-5p was 
confirmed by qPCR showing significant down-regulation in active CMA patients versus 
healthy controls (P<0.05). The horizontal bars represent the mean values and the range. 
Figure 2. Evaluation of miR-193a-5p targets.  
(A) Interaction network of miR-193a-5p-targets obtained from miRTarBase database 
showing that it has four targets: RPL35A, TP73, ZC3H7B and C/EBP. Junction:11; 
Edge:11. The blue junctions represent an interaction between the edges, for which there is 
strong evidence (reporter assay, western blot, qRT-PCR or qPCR); the light blue junctions 
represent an interaction between the edges with evidence of cross linking, ligation, and 
sequencing of hybrids (CLASH). The CLASH method is based on high-throughput mapping 
of RNA-RNA interactions. miR-193a-5p predicted targets were evaluated by qPCR in active 
CMA patients versus healthy controls (B) C/EBPα transcript shows a trend in up-regulation 
in active CMA patients versus controls. (C) RPL35A transcript was significantly up-
regulated in active CMA patients versus controls (***=P<0.001) (D) The relative expression 
of TP73 transcript shows significant up-regulation in active CMA subjects versus healthy 
controls (*=P<0.05) (E) ZC3H7B transcript was significantly up-regulated in active CMA 
subjects versus healthy controls (***=P<0.001). 
Figure 3. Functional assessment of IL-4 expression depending on miR-193a-5p 
inhibition.  
(A) IL-4 mRNA and protein levels were assessed by qPCR and ELISA, respectively, in 
CD4+ T cells from a healthy human donor. CD4+ T cells, transfected with miR193a-5 
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inhibitor, showed a higher IL-4 expression compared to unstimulated CD4+T cells (negative 
control) (B) Accordingly IL-4 protein, as assessed by ELISA, showed a corresponding 
increase in protein level in CD4+ T cells transfected with miR193a-5 inhibitor.  
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Figure 2 
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Figure 3 
 
 
 
 
 
 
